BIOLIFE SOLUTIONS INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that BIOLIFE SOLUTIONS INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2014 | $6.19M | Mar 12, 2015 |
| FY2014 | Dec 31, 2013 | $8.95M | Mar 12, 2015 |
| FY2013 | Dec 31, 2012 | $5.66M | Feb 12, 2014 |
| FY2012 | Dec 31, 2011 | $2.76M | Mar 29, 2013 |
| FY2011 | Dec 31, 2010 | $2.08M | Mar 29, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $62.12M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $50.10M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $41.32M | Feb 26, 2026 |
| FY2018 | Dec 31, 2018 | $13.53M | Mar 15, 2019 |
| FY2018 | Dec 31, 2017 | $6.75M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $4.78M | Mar 9, 2018 |
| FY2016 | Dec 31, 2015 | $3.81M | Mar 15, 2017 |
| FY2015 | Dec 31, 2014 | $3.04M | Feb 25, 2016 |
| FY2014 | Dec 31, 2013 | $3.76M | Mar 12, 2015 |
| FY2013 | Dec 31, 2012 | $2.29M | Feb 12, 2014 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.60M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($20.18M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($68.00M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($139.81M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | ($8.91M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $1.98M | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | ($1.66M) | Mar 31, 2022 |
| FY2019 | Sep 30, 2019 | $10.27M | May 15, 2020 |
| FY2019 | Jun 30, 2019 | $4.25M | May 15, 2020 |
| FY2019 | Mar 31, 2019 | ($19.16M) | May 15, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($16.60M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($4.48M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($17.21M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($5.92M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | ($35.16M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($6.24M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | ($220.0K) | Mar 31, 2022 |
| FY2019 | Sep 30, 2019 | ($772.0K) | May 15, 2020 |
| FY2019 | Jun 30, 2019 | $747.0K | May 15, 2020 |
| FY2019 | Mar 31, 2019 | $566.0K | May 15, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.57M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $4.75M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $5.52M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $8.67M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $11.82M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $6.72M | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | $3.17M | Mar 31, 2022 |
| FY2019 | Sep 30, 2019 | $1.03M | May 15, 2020 |
| FY2019 | Jun 30, 2019 | $691.0K | May 15, 2020 |
| FY2019 | Mar 31, 2019 | $359.0K | May 15, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.12M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $8.43M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($12.50M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($8.49M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | ($4.59M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $6.65M | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | $1.21M | Mar 31, 2022 |
| FY2019 | Sep 30, 2019 | $2.22M | May 15, 2020 |
| FY2019 | Jun 30, 2019 | $1.08M | May 15, 2020 |
| FY2019 | Mar 30, 2019 | $1.15M | May 15, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.48M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $3.23M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $6.38M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $10.39M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $8.39M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $1.96M | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | $675.0K | Mar 31, 2022 |
| FY2019 | Sep 30, 2019 | $356.0K | May 15, 2020 |
| FY2019 | Jun 30, 2019 | $267.0K | May 15, 2020 |
| FY2019 | Mar 30, 2019 | $156.0K | May 15, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $405.88M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $399.49M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $412.71M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $450.23M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $554.29M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $234.83M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $92.82M | Mar 31, 2021 |
| FY2019 | Sep 30, 2019 | $83.79M | May 15, 2020 |
| FY2019 | Jun 30, 2019 | $51.30M | May 15, 2020 |
| FY2019 | Mar 31, 2019 | $48.07M | May 15, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $34.00M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $50.58M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $75.05M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $86.04M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $76.24M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $29.58M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $49.36M | Mar 31, 2021 |
| FY2019 | Sep 30, 2019 | $48.60M | May 15, 2020 |
| FY2019 | Jun 30, 2019 | $49.23M | May 15, 2020 |
| FY2019 | Mar 31, 2019 | $51.81M | May 15, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $371.89M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $348.91M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $337.66M | Feb 26, 2026 |
| FY2025 | Dec 31, 2022 | $364.19M | Feb 26, 2026 |
| FY2024 | Dec 31, 2021 | $478.05M | Mar 3, 2025 |
| FY2023 | Dec 31, 2020 | $204.43M | Feb 29, 2024 |
| FY2022 | Dec 31, 2019 | $43.32M | Mar 31, 2023 |
| FY2019 | Sep 30, 2019 | $35.19M | May 15, 2020 |
| FY2019 | Jun 30, 2019 | $2.07M | May 15, 2020 |
| FY2019 | Mar 31, 2019 | ($3.74M) | May 15, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $208.59M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $208.59M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $212.30M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $224.74M | Feb 29, 2024 |
| FY2023 | Dec 31, 2021 | $58.45M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $58.45M | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | $33.64M | Mar 31, 2022 |
| FY2019 | Sep 30, 2019 | $28.34M | May 15, 2020 |
| FY2019 | Jun 30, 2019 | $9.52M | May 15, 2020 |
| FY2020 | Dec 31, 2018 | $0 | Mar 31, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($339.70M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($335.10M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($314.92M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | ($246.92M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | ($107.11M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($97.39M) | Mar 31, 2022 |
| FY2022 | Dec 31, 2019 | $100.20M | Mar 31, 2023 |
| FY2019 | Sep 30, 2019 | ($103.04M) | May 15, 2020 |
| FY2019 | Jun 30, 2019 | ($113.30M) | May 15, 2020 |
| FY2019 | Mar 31, 2019 | ($117.56M) | May 15, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $33.04M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $91.54M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $27.90M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $19.44M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $69.86M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $90.40M | Mar 31, 2022 |
| FY2021 | Dec 31, 2019 | $6.45M | Mar 31, 2022 |
| FY2019 | Sep 30, 2019 | $21.21M | May 15, 2020 |
| FY2019 | Jun 30, 2019 | $19.62M | May 15, 2020 |
| FY2019 | Mar 31, 2019 | $31.82M | May 15, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.00M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $15.94M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $23.85M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $25.61M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $7.22M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.27M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $13.0K | Mar 31, 2021 |
| FY2016 | Dec 31, 2016 | $4.25M | Mar 15, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | (3) | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Mar 31, 2022 |
| FY2019 | Sep 30, 2019 | 0 | May 15, 2020 |
| FY2019 | Jun 30, 2019 | 0 | May 15, 2020 |
| FY2019 | Mar 31, 2019 | (1) | May 15, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | (3) | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Mar 31, 2022 |
| FY2019 | Sep 30, 2019 | 0 | May 15, 2020 |
| FY2019 | Jun 30, 2019 | 0 | May 15, 2020 |
| FY2019 | Mar 31, 2019 | (1) | May 15, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 48.20M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 46.91M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 45.17M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | 42.83M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | 41.82M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 33.04M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 20.83M | Mar 31, 2021 |
| FY2019 | Sep 30, 2019 | 20.34M | May 15, 2020 |
| FY2019 | Jun 30, 2019 | 18.90M | May 15, 2020 |
| FY2019 | Mar 31, 2019 | 18.72M | May 15, 2020 |